RE: Re: Targeted Proteins & designer antibodies

[Guest guest]

That's how I see the [possible] answer to this ..The adaptive immune system identifies, responds and remembers, but in the case of stealth pathogens ,this obviously doesn't happen , or to be more accurate not in the appropriate robust manner

Designer antibodies binding to genetically tagged antigens that mark it for destruction is a possibility, see the site below , as you see the technology is there.

Or perhaps a self-antigen a molecule that is produced by the body to stimulate adaptive immunity. again perhaps a designer self antigen ...

On the subject , Malaria is another infection that is very difficult to eradicate, it's interesting that the scientists have found a defensive tactic from the parasite is to change the proteins on its surface ..something that has been suspected of nano CWD bacteria

http://www.markergene.com/WebNewsletter10.2.htm

Science shows how Malaria hides

http://news.bbc.co.uk/1/hi/health/4419835.stm

-----Original Message-----From: infections [mailto:infections ]On Behalf Of jill1313Sent: 25 April 2005 02:23infections Subject: [infections] Re: Targeted Proteins vs West Nile Virus - More from Today's NewsThis is very cool.There's a company called Neutec and I've been meanign to contact them. They make mycograb and aurograb. I'd like to try mycograb but it might be kind of expensive....at the moment...I wanted to ask them to make a borrelia grab. My only worry is I recall the 6 main antigens borrelia uses are on its inside, somehow, and the decoy ones that change are on the surface.> > http://tinyurl.com/bkm74> > Targeted Proteins May Treat West Nile-Researchers> > Sun Apr 24, 4:02 PM ET Health - Reuters > > WASHINGTON (Reuters) - Targeted proteins called monoclonal > antibodies may work to treat West Nile virus, a mosquito-borne > disease that came to North America in 1999, researchers said on > Sunday. > > They found the laboratory-engineered antibodies cured mice infected > with the virus, which usually causes only mild fever but which can > cause deadly brain inflammation in some patients. > > "We could give this antibody to mice as long as five days after > infection, when West Nile virus had entered the brain, and it could > still cure them," said Dr. Diamond of Washington University > in St. Louis, who led the study. > > "It also completely protected the mice against death." > > West Nile, common in North Africa, parts of Europe and the Middle > East, first appeared in New York in 1999 and quickly spread across > the continent, affecting Canada and Mexico as well. > > It infects birds, horses and people and is spread by mosquitoes. In > 2003 it infected a reported 2,300 people and killed 264, according > to the U.S. Centers for Disease Control and Prevention. In 2004 it > infected 2,470 and killed 88. > > "West Nile virus has emerged in the United States as a regular > seasonal threat, particularly for people over 50," said Dr. > Fauci, head of the National Institute for Allergy and Infectious > Diseases, which funded the study. > > "We currently do not have a proven therapy for people with serious > West Nile disease, so we will continue to aggressively pursue all > promising leads for an effective treatment," Fauci said in a > statement. > > The researchers decided to develop monoclonal antibody after finding > that antibodies taken from the blood of people who recovered from > West Nile fever could cure mice infected with West Nile virus. > Writing in the journal Nature Medicine, the team said it made 46 > monoclonal antibodies and screened them until they found the most > effective ones against West Nile virus. > > Rockville, land-based MacroGenics Inc., made a human-like > version of the most effective antibody. > > They tested it in mice bred to be susceptible to West Nile virus. It > protected them from death even if they got severe cases of the > disease. > > "Our results are the first successful demonstration of a humanized > monoclonal antibody as postexposure therapy against a viral disease > and suggest that antibody-based therapeutics may have more broad > utility than previously appreciated, especially in the treatment of > central nervous system infections," they wrote.